Cellular Biomedicine Group Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|---|
| MRK | Merck | Outperform |
2
|
$131.09 | Buy/Sell | $130.51 | 9.85% | 11 | $332.03B |
| ABT | Abbott Laboratories | Outperform |
9
|
$104.23 | Buy/Sell | $118.92 | 19.93% | 7 | $181.32B |
| PFE | Pfizer | Outperform |
2
|
$28.69 | Buy/Sell | $32.87 | 6.31% | 6 | $162.57B |
| MDT | Medtronic | Outperform |
11
|
$81.38 | Buy/Sell | $92.47 | 17.97% | 9 | $108.06B |
| GSK | GSK | Outperform |
12
|
£17.78 | Buy/Sell | £17.30 | 12.20% | 12 | £72.51B |
| ACOR | Acorda Therapeutics | - |
5
|
$0.75 | Buy/Sell | $200.00 | -100.00% | 1 | $0.53M |
| 542765 | Transpact Enterprises | - |
0
|
342.95 | Buy/Sell | 0.00 | -100.00% | 0 | 139.61M |